JP2020512343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512343A5 JP2020512343A5 JP2019552983A JP2019552983A JP2020512343A5 JP 2020512343 A5 JP2020512343 A5 JP 2020512343A5 JP 2019552983 A JP2019552983 A JP 2019552983A JP 2019552983 A JP2019552983 A JP 2019552983A JP 2020512343 A5 JP2020512343 A5 JP 2020512343A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- heterocyclyl
- alkyl
- halo
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 130
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- -1 isooxazolyl Chemical group 0.000 claims description 80
- 229910052739 hydrogen Inorganic materials 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 79
- 150000002431 hydrogen Chemical class 0.000 claims description 67
- 125000001424 substituent group Chemical group 0.000 claims description 61
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000003386 piperidinyl group Chemical group 0.000 claims description 20
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 17
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 17
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000004193 piperazinyl group Chemical group 0.000 claims description 14
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 13
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 10
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 10
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 10
- 125000002393 azetidinyl group Chemical group 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 claims description 5
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 5
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 5
- 230000004545 gene duplication Effects 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims 52
- 239000008194 pharmaceutical composition Substances 0.000 claims 50
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- PIINXYKJQGMIOZ-UHFFFAOYSA-N 1,2-dipyridin-2-ylethane-1,2-dione Chemical compound C=1C=CC=NC=1C(=O)C(=O)C1=CC=CC=N1 PIINXYKJQGMIOZ-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 26
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- SJHNWSAWWOAWJH-MRXNPFEDSA-N Cc1nccc(-c2nc(C(Nc3c(N(CC4)C[C@@H]4O)nc4nc(N5CCOCC5)[o]c4c3)=O)c[o]2)c1 Chemical compound Cc1nccc(-c2nc(C(Nc3c(N(CC4)C[C@@H]4O)nc4nc(N5CCOCC5)[o]c4c3)=O)c[o]2)c1 SJHNWSAWWOAWJH-MRXNPFEDSA-N 0.000 description 1
- 0 OCCNc([s]c1c2)nc1nc(N1CCCCC1)c2NC(c1cccc(N2C*CC2)n1)=O Chemical compound OCCNc([s]c1c2)nc1nc(N1CCCCC1)c2NC(c1cccc(N2C*CC2)n1)=O 0.000 description 1
- GTKVXHNHLXCCTB-UHFFFAOYSA-N [1-[1-(2-methoxyethyl)-5-[2-(2-methylpyridin-4-yl)-2H-1,3-oxazol-3-yl]indazol-6-yl]piperidin-4-yl]methanamine Chemical compound COCCn1ncc2cc(N3C=COC3c3ccnc(C)c3)c(cc12)N1CCC(CN)CC1 GTKVXHNHLXCCTB-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023129903A JP2023154005A (ja) | 2017-03-31 | 2023-08-09 | 血液疾患を処置するための化合物及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741011785 | 2017-03-31 | ||
| IN201741011785 | 2017-03-31 | ||
| PCT/IB2018/052232 WO2018178947A2 (en) | 2017-03-31 | 2018-03-30 | Compounds and compositions for treating hematological disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129903A Division JP2023154005A (ja) | 2017-03-31 | 2023-08-09 | 血液疾患を処置するための化合物及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512343A JP2020512343A (ja) | 2020-04-23 |
| JP2020512343A5 true JP2020512343A5 (https=) | 2021-05-06 |
| JP7333136B2 JP7333136B2 (ja) | 2023-08-24 |
Family
ID=63677680
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552983A Active JP7333136B2 (ja) | 2017-03-31 | 2018-03-30 | 血液疾患を処置するための化合物及び組成物 |
| JP2023129903A Withdrawn JP2023154005A (ja) | 2017-03-31 | 2023-08-09 | 血液疾患を処置するための化合物及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129903A Withdrawn JP2023154005A (ja) | 2017-03-31 | 2023-08-09 | 血液疾患を処置するための化合物及び組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11419875B2 (https=) |
| EP (2) | EP3600270B1 (https=) |
| JP (2) | JP7333136B2 (https=) |
| KR (3) | KR20240019391A (https=) |
| CN (2) | CN120267671A (https=) |
| AU (2) | AU2018242623B2 (https=) |
| BR (1) | BR112019018991A2 (https=) |
| CA (1) | CA3056893A1 (https=) |
| DK (1) | DK3600270T3 (https=) |
| EA (1) | EA201992322A3 (https=) |
| ES (1) | ES2950764T3 (https=) |
| FI (1) | FI3600270T3 (https=) |
| HR (1) | HRP20230657T8 (https=) |
| HU (1) | HUE062648T2 (https=) |
| IL (4) | IL293783B2 (https=) |
| LT (1) | LT3600270T (https=) |
| MX (2) | MX389825B (https=) |
| PH (1) | PH12019502138A1 (https=) |
| PL (1) | PL3600270T3 (https=) |
| PT (1) | PT3600270T (https=) |
| RS (1) | RS64411B1 (https=) |
| SG (1) | SG11201908171TA (https=) |
| SI (1) | SI3600270T1 (https=) |
| SM (1) | SMT202300236T1 (https=) |
| WO (1) | WO2018178947A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| EP3600270B1 (en) | 2017-03-31 | 2023-06-14 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| WO2021004533A1 (zh) * | 2019-07-10 | 2021-01-14 | 南京明德新药研发有限公司 | 作为irak4和btk多靶点抑制剂的噁唑类化合物 |
| CN112480101B (zh) * | 2019-09-12 | 2022-11-25 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
| HRP20241159T1 (hr) | 2020-02-07 | 2024-12-06 | Gasherbrum Bio, Inc. | Heterociklički agonisti za glp-1 |
| WO2021204589A1 (en) | 2020-04-07 | 2021-10-14 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
| IL300310A (en) * | 2020-08-03 | 2023-04-01 | Curis Inc | Preparations and methods for treating diseases and disorders |
| CN116368140A (zh) | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| MX2023005591A (es) * | 2020-11-18 | 2023-05-29 | Curis Inc | Metodos de tratamiento de enfermedades y trastornos. |
| CN116745294A (zh) * | 2020-12-25 | 2023-09-12 | 南京明德新药研发有限公司 | 酰胺噁唑类化合物 |
| WO2022156788A1 (zh) * | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 苯并咪唑化合物及其用途 |
| EP4319750A4 (en) * | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
| TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
| WO2023088435A1 (zh) * | 2021-11-19 | 2023-05-25 | 成都奥睿药业有限公司 | 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用 |
| EP4434981A4 (en) * | 2021-12-23 | 2025-08-20 | Hangzhou Polymed Biopharmaceuticals Inc | FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE |
| JP2025516501A (ja) * | 2022-05-11 | 2025-05-30 | キュリス，インコーポレイテッド | Ｉｒａｋ４修飾化合物による疾患及び障害の治療 |
| CN120957993A (zh) | 2023-02-16 | 2025-11-14 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| ES2102367T3 (es) | 1990-05-18 | 1997-08-01 | Hoechst Ag | Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion. |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| DE69839355T2 (de) | 1997-07-29 | 2009-06-04 | Alcon Laboratories, Inc., Fort Worth | Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| EP2385041B1 (en) | 2003-05-01 | 2013-09-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
| EP1627869B1 (en) | 2003-05-20 | 2012-05-02 | Ajinomoto Co., Inc. | Vanilloid receptor modulators |
| EP1628661A2 (en) | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| MXPA06003949A (es) | 2003-10-07 | 2006-06-27 | Renovis Inc | Compuestos amida como ligandos del canal de ion y su uso. |
| CA2563941C (en) | 2004-04-22 | 2014-10-07 | Bayer Cropscience Lp | Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| WO2006066174A1 (en) | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
| DE602005009021D1 (de) | 2004-12-17 | 2008-09-25 | Lilly Co Eli | Neue mch-rezeptorantagonisten |
| EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| CN101379060B (zh) | 2006-02-10 | 2012-05-23 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
| CA2644910C (en) | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
| US20080293785A1 (en) | 2006-04-11 | 2008-11-27 | Connolly Peter J | Substituted benzothiazole kinase inhibitors |
| CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| EP2061786A2 (en) | 2006-09-07 | 2009-05-27 | Biogen Idec MA Inc. | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CA2690557A1 (en) * | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| ES2457418T3 (es) | 2007-07-16 | 2014-04-25 | Abbvie Inc. | Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas |
| CN101790519B (zh) | 2007-08-08 | 2013-10-16 | 默克雪兰诺有限公司 | 用于治疗多发性硬化症的结合于鞘氨醇1-磷酸(s1p)的6-氨基-嘧啶-4-羧酰胺衍生物及相关化合物 |
| WO2009102468A1 (en) | 2008-02-13 | 2009-08-20 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| WO2010008847A2 (en) * | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
| CN102281919A (zh) | 2008-11-19 | 2011-12-14 | 先灵公司 | 二酰基甘油酰基转移酶的抑制剂 |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| WO2010072599A1 (en) | 2008-12-23 | 2010-07-01 | F. Hoffmann-La Roche Ag | Dihydropyridone ureas as p2x7 modulators |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| MX2012001974A (es) | 2009-08-19 | 2012-04-11 | Ambit Biosciences Corp | Compuestos de biarilo y metodos de uso de los mismos. |
| WO2011046954A1 (en) | 2009-10-13 | 2011-04-21 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
| US8822447B2 (en) | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| US20130053382A1 (en) | 2010-04-30 | 2013-02-28 | Sunil Paliwal | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
| RS56332B1 (sr) | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| CN110003219A (zh) | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| RU2632900C2 (ru) | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| BR112013015460B1 (pt) | 2010-12-20 | 2022-01-25 | Merck Serono S.A. | Derivados de indazolil triazol, kit, e composição farmacêutica |
| EP2696873B1 (en) | 2011-04-12 | 2022-08-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
| WO2013042137A1 (en) * | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| AU2012322095B2 (en) * | 2011-10-14 | 2017-06-29 | Ambit Biosciences Corporation | Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases |
| JP6073343B2 (ja) | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
| WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP6372666B2 (ja) | 2012-11-03 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | サイトメガロウイルスの阻害剤 |
| EP2999470B1 (en) | 2013-05-22 | 2017-08-16 | Children's Hospital Medical Center | Combination therapy for mds |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| EP3092226B1 (en) | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| LT3466955T (lt) * | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| US9452986B2 (en) | 2014-02-06 | 2016-09-27 | Abbvie Inc. | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use |
| AU2015275730A1 (en) | 2014-06-20 | 2016-12-15 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as IRAK4 inhibitors |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| JP2018524372A (ja) | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物 |
| CN108024971A (zh) | 2015-07-15 | 2018-05-11 | 奥列基因发现技术有限公司 | 作为irak-4抑制剂的取代的氮杂化合物 |
| DK3331879T3 (da) | 2015-08-04 | 2020-08-10 | Rigel Pharmaceuticals Inc | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne |
| WO2018081738A1 (en) | 2016-10-28 | 2018-05-03 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
| EP3600270B1 (en) | 2017-03-31 | 2023-06-14 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| HUE067356T2 (hu) | 2017-10-31 | 2024-10-28 | Curis Inc | IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra |
-
2018
- 2018-03-30 EP EP18777745.3A patent/EP3600270B1/en active Active
- 2018-03-30 JP JP2019552983A patent/JP7333136B2/ja active Active
- 2018-03-30 LT LTEPPCT/IB2018/052232T patent/LT3600270T/lt unknown
- 2018-03-30 HU HUE18777745A patent/HUE062648T2/hu unknown
- 2018-03-30 EP EP23173240.5A patent/EP4252853A3/en active Pending
- 2018-03-30 CA CA3056893A patent/CA3056893A1/en active Pending
- 2018-03-30 SM SM20230236T patent/SMT202300236T1/it unknown
- 2018-03-30 US US16/498,866 patent/US11419875B2/en active Active
- 2018-03-30 WO PCT/IB2018/052232 patent/WO2018178947A2/en not_active Ceased
- 2018-03-30 IL IL293783A patent/IL293783B2/en unknown
- 2018-03-30 BR BR112019018991-2A patent/BR112019018991A2/pt active Search and Examination
- 2018-03-30 HR HRP20230657TT patent/HRP20230657T8/hr unknown
- 2018-03-30 SI SI201830946T patent/SI3600270T1/sl unknown
- 2018-03-30 IL IL269536A patent/IL269536B/en unknown
- 2018-03-30 IL IL316364A patent/IL316364A/en unknown
- 2018-03-30 KR KR1020247003678A patent/KR20240019391A/ko not_active Ceased
- 2018-03-30 AU AU2018242623A patent/AU2018242623B2/en active Active
- 2018-03-30 DK DK18777745.3T patent/DK3600270T3/da active
- 2018-03-30 EA EA201992322A patent/EA201992322A3/ru unknown
- 2018-03-30 ES ES18777745T patent/ES2950764T3/es active Active
- 2018-03-30 KR KR1020197032104A patent/KR102633530B1/ko active Active
- 2018-03-30 PL PL18777745.3T patent/PL3600270T3/pl unknown
- 2018-03-30 SG SG11201908171T patent/SG11201908171TA/en unknown
- 2018-03-30 PT PT187777453T patent/PT3600270T/pt unknown
- 2018-03-30 RS RS20230544A patent/RS64411B1/sr unknown
- 2018-03-30 KR KR1020257014711A patent/KR20250065441A/ko active Pending
- 2018-03-30 IL IL305150A patent/IL305150B2/en unknown
- 2018-03-30 CN CN202510475412.9A patent/CN120267671A/zh active Pending
- 2018-03-30 CN CN201880022870.5A patent/CN110691589A/zh active Pending
- 2018-03-30 MX MX2019011158A patent/MX389825B/es unknown
- 2018-03-30 FI FIEP18777745.3T patent/FI3600270T3/fi active
-
2019
- 2019-09-18 PH PH12019502138A patent/PH12019502138A1/en unknown
- 2019-09-19 MX MX2022001343A patent/MX2022001343A/es unknown
-
2022
- 2022-06-29 US US17/853,299 patent/US20220339161A1/en active Pending
-
2023
- 2023-08-09 JP JP2023129903A patent/JP2023154005A/ja not_active Withdrawn
-
2024
- 2024-06-11 AU AU2024203943A patent/AU2024203943A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512343A5 (https=) | ||
| US20230346927A1 (en) | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | |
| CA2984259C (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| JP2021501145A5 (https=) | ||
| CN107857755B (zh) | 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物 | |
| JP6342393B2 (ja) | 置換型ピラゾロン化合物及び使用方法 | |
| RU2665036C2 (ru) | Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения | |
| CA2351725A1 (en) | Substituted pyrazoles as p38 kinase inhibitors | |
| JP2006502112A5 (https=) | ||
| MX2010012290A (es) | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. | |
| TW201249823A (en) | Tetrasubstituted cyclohexyl compounds as kinase inhibitors | |
| JP2018515555A5 (https=) | ||
| IL305843B1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors | |
| JP2004506736A5 (https=) | ||
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| JP2010524974A5 (https=) | ||
| JP2024516353A5 (https=) | ||
| JP2016516791A5 (https=) | ||
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| JP2018532788A5 (https=) | ||
| US12202816B2 (en) | Compounds as NADPH oxidase inhibitors | |
| WO2014022128A1 (en) | Pi3 kinase modulators and methods of use | |
| JP2008517042A5 (https=) | ||
| WO2018153971A1 (en) | Combination of atr kinase inhibitors | |
| CN1980912A (zh) | 吡唑衍生物 |